A large clinical trial is challenging a familiar question in preventive cardiology: how should clinicians decide which people are most likely to benefit from statins?
The study, involving nearly 5,800 adults, compared conventional cardiovascular-risk assessment with an approach that uses coronary artery calcium scans to guide treatment decisions. Researchers reported the same observed rate of major cardiovascular events over four years in the two groups, despite the scan-guided strategy resulting in recommendations for statins far less often.
The result does not settle whether calcium-scan guidance is equivalent to conventional assessment. The researchers explicitly said the trial did not establish that the scan-based approach was as effective. But it adds evidence that imaging may help make preventive-treatment discussions more targeted—and it highlights medication adherence as a central part of the equation.
Risk estimates versus visible plaque
Cardiovascular disease remains the world’s leading cause of illness and death. A major share of that burden is associated with atherosclerotic cardiovascular disease, in which plaque accumulates inside arteries and can restrict blood flow, contributing to heart attacks and strokes.
Clinicians commonly estimate a person’s risk using established factors including smoking, diabetes, high blood pressure and cholesterol levels. Those estimates help determine whether preventive medicines such as statins are appropriate.
Coronary artery calcium scanning takes a different route. It measures calcium buildup in the coronary arteries, offering a direct indicator associated with atherosclerotic plaque. In the trial, that information was used to guide recommendations about beginning statin treatment.
The scan-guided group received fewer recommendations to start statins than people evaluated through traditional risk assessment. Yet over four years, the observed incidence of major cardiovascular events was the same in the two strategies.
Adherence was markedly higher
The study’s most striking difference was not the event count, but what happened after a treatment recommendation. Participants advised to take statins on the basis of their scan results were nearly three times as likely to follow that advice as those assessed through the conventional approach.
That finding matters because preventive medicines can only reduce risk when patients are willing and able to take them consistently. The trial suggests that seeing evidence of calcium buildup may make the rationale for treatment more concrete to patients, though the study does not establish why adherence differed.
For clinicians, the findings raise two linked questions. First, can coronary calcium scans identify people for whom statin treatment is most useful while avoiding recommendations for others? Second, can a more personalized discussion of risk improve the likelihood that patients follow through with preventive care?
What the trial does—and does not—show
The trial provides an observed comparison over four years, not proof that the two methods produce identical clinical outcomes. The researchers cautioned that further studies are needed to determine whether scan-guided treatment is a better approach to preventing cardiovascular disease.
That distinction is important. Similar observed event rates in one study do not by themselves demonstrate that a scan-based strategy can replace established risk assessment across populations or care settings. Decisions about statins also involve individual health history, risk factors and discussions between patients and clinicians.
Still, the results point to a potential shift in emphasis. Rather than relying only on statistical estimates derived from multiple risk factors, prevention strategies may be able to incorporate imaging evidence of disease burden. If that evidence also improves adherence, it could change how clinicians communicate the value of long-term preventive treatment.
A question for preventive care
Statins are among the most widely used medicines for lowering cardiovascular risk. The new findings do not argue that fewer people should automatically receive them. Instead, they suggest that the way treatment decisions are explained and tailored may influence both who is advised to start therapy and whether those patients ultimately take it.
As additional research examines the approach, the central goal remains unchanged: preventing heart attacks and strokes before they occur. The trial indicates that coronary artery calcium scans could become an important tool in that effort, but it also underscores that better targeting must be tested carefully before it is treated as a replacement for conventional risk assessment.
This article is based on reporting by Science Daily. Read the original article.
Originally published on sciencedaily.com
